Milrinone Tillomed (Milrinone)

Milrinone acts as an inotropic and vasodilator agent in acute cardiac conditions.

• Acute decompensated heart failure: improves contractility and reduces systemic vascular resistance, helping restore adequate circulation.
• Cardiogenic shock: provides rapid inotropic support to maintain organ perfusion during severe circulatory collapse.
• Post‑cardiac surgery low‑output syndrome: assists in stabilising hemodynamics when the heart fails to generate sufficient output after operative procedures.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes in cardiac and vascular smooth‑muscle cells, leading to accumulation of intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP enhances calcium influx during systole, producing a positive inotropic effect, while simultaneously promoting smooth‑muscle relaxation, resulting in vasodilation and reduced afterload.

Milrinone may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Hypotension: drop in blood pressure, especially with rapid infusion.
• Arrhythmias: premature ventricular contractions or tachycardia.
• Headache: mild to moderate intensity.
• Nausea or vomiting: gastrointestinal discomfort.
• Flushing: transient warmth and redness of the skin.
• Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects

• Severe ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain due to reduced coronary perfusion.
• Extreme hypotension: profound drop in blood pressure requiring intervention.
• Anaphylactic or severe allergic reactions: rash, bronchospasm, or shock.
• Thrombosis: formation of clots in veins or arteries.

Milrinone requires careful monitoring and specific safety measures before and during therapy.

• Blood pressure monitoring: watch for hypotension, especially during dose titration.
• Cardiac rhythm surveillance: continuous ECG to detect arrhythmias.
• Renal function assessment: dose may need adjustment in renal impairment.
• Severe aortic stenosis: avoid use due to risk of excessive afterload reduction.
• Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase milrinone plasma levels.
• Concurrent use with other phosphodiesterase inhibitors: risk of profound vasodilation.
• Nitrates or other potent vasodilators: can cause severe hypotension.
• High‑dose β‑agonists: may precipitate arrhythmias.
• Digoxin: combined use may heighten arrhythmic risk.

Moderate Interactions (Monitor Closely)

• Diuretics: may amplify electrolyte shifts and hypotension.
• ACE inhibitors or ARBs: additive blood‑pressure lowering effect.
• Anticoagulants: monitor for bleeding if thrombocytopenia occurs.
• Beta‑blockers: may blunt desired inotropic response.
• Other inotropes: careful titration required to avoid over‑stimulation.